Log in

Company updateBusiness Standard

Ichnos Glenmark files US FDA application for solid tumour drug

Positive+192 sources

GreyOak summary

Ichnos Glenmark Innovation, a joint venture between Glenmark Pharmaceuticals and Ichnos Sciences, submitted an investigational new drug application to the US FDA for ISB 2301. This first-in-class pentaspecific molecule targets solid tumours and is planned for a Phase I clinical trial in 2027. The submission marks a milestone in expanding the company's oncology pipeline beyond blood cancers.

What it affects

Source

Read the original at Business Standard

More Glenmark Pharmaceuticals news

All Glenmark Pharmaceuticals news →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy